Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat

Drug Metabolism and Disposition

Volumn 24, Issue 6, 1996, Pages 619-627

  Panesar, Sukhbinder K ^a,b   Bandiera, Stelvio M ^a   Abbott, Frank S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Geneva Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450; LIVER ENZYME; PHENOBARBITAL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; EPILEPSY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CARBAMAZEPINE; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; MALE; MICROSOMES, LIVER; PHENOBARBITAL; RATS; STEROID HYDROXYLASES;

EID: 0029895113     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. P. Loiseau and B. Duche: Carbamazepine clinical use. In "Antiepileptic Drugs," ed. 3 (R. Levy, R. Mattson, B. Meldrum, J. K. Penry, and F. E. Dreifuss, eds.), pp. 533-554. Raven Press, New York, 1989.
2. L. Bertilsson and T. Tomson: Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin. Pharmacokinet. 11, 177-198 (1986).
3. J. M. Pellock: Carbamazepine side effects in children and adults. Epilepsia 28 (Suppl. 3) S64-S70 (1987).
4. N. H. Shear, S. P. Speilberg, M. Cannon, and M. Miller: Anticonvulsant hypersensitivity syndrome: in vitro risk assessment. J. Clin. Invest. 82, 1826-1832 (1988).
5. M. Pirmohamed, A. Graham, P. Roberts, D. Smith, D. Chadwick, A. M. Breckenridge, and B. K. Park: Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br. J. Clin. Pharmacol. 32, 741-749 (1991).
6. M. Eichelbaum, T. Tomson, G, Tybring, and L. Bertilsson: Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin. Pharmacokinet. 10, 80-90 (1985).
7. E. Spina, C. Martines, A. Fazio, R. Trio, F. Pisani, and T. Tomson: Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther. Drug Monit. 13, 109-112 (1991).
8. R. Hedrick, F. Williams, R. Morin, W. A. Lamb, and J. C. Cates IV: Carbamazepine-erythromycin interaction leading to carbamazepine toxicity in four epileptic children. Ther. Drug Monit. 5, 405-407 (1983).
9. T. A. Moreland, B. K. Park, and G. W. Rylance: Microsomal enzyme induction in children: The influence of carbamazepine treatment on antipyrine kinetics, 6-β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity. Br. J. Clin. Pharmacol. 14, 861-865 (1982).
10. E. Leinonen, P. Lillsunde, V. Laukkanen, and P. Ylitalo: Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J. Clin. Psychopharmacol. 11, 313-318 (1991).
11. P. L. Morselli and A. Frigerio: Metabolism and pharmacokinetics of carbamazepine. Drug Metab. Rev. 4, 97-113 (1975).
12. G. Tybring, C. von Bahr, L. Bertilsson, H. Collste, H. Glaumann, and M. Solbrand: Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab. Dispos. 9, 561-564 (1981).
13. K. Lertratanangkoon and M. G. Horning: Metabolism of carbamazepine. Drug Metab. Dispos. 10, 1-10 (1982).
14. M. Eichelbaum, C. Jensen, W. von Sassen, L. Bertilsson, and T. Tomson: In vivo and in vitro biotransformation of carbamazepine in man and rat. In "Metabolism of Antiepileptic Drugs" (R. H. Levy, W. H. Pitlick, M. Eichelbaum, and J. Meijer, eds.), pp. 27-34. Raven Press, New York, 1984.
15. J. W. Faigle and K. F. Feldmann: Carbamazepine biotransformation. In "Antiepileptic Drugs," ed. 3 (R. Levy, R. Mattson, B. Meldrum, J. K. Penry, and F. E. Dreifuss, eds.), pp. 491-504. Raven Press, New York, 1989.
16. H. Liu and M. R. Delgado: The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children. Epilepsy Res. 17, 257-269 (1994).
17. T. Tomson, O Almkvist, B. Y. Nilsson, J.-O. Svensson, and L. Bertilsson: Carbamazepine-10,11-epoxide in epilepsy: a pilot study. Arch. Neurol. 47, 888-892 (1990).
18. B. M. Kerr and R. H. Levy: Carbamazepine: carbamazepine epoxide. In "Antiepileptic Drugs," ed. 3 (R. Levy, R. Mattson, B. Meldrum, J. K. Penry and F. E. Dreifuss, eds.), pp. 505-520. Raven Press, New York, 1989.
19. T. Tomson, G. Tybring, and L. Bertilsson: Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin. Pharmacol. Ther. 33, 58-65 (1983).
20. E. Spina, T. Tomson, J.-O. Svensson, J. W. Faigle, and L. Bertilsson: Single-dose kinetics of an enteric coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther. Drug Monit. 10, 382-385 (1988).
21. L. Bertilsson, B. Hojer, G. Tybring, J. Osterloh, and A. Rane: Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin. Pharmacol. Ther. 27, 83-88 (1980).
22. T. B. Kudriakova, L. A. Sirota, G. I. Rozova, and V. A. Gorkov: Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br. J. Clin. Pharmacol. 33, 611-615 (1992).
23. I. Bernus, R. G. Dickinson, W. D. Hooper, and M. J. Eadie: Early stage autoinduction of carbamazepine metabolism in humans. Pharmacokinet. Disp. 47, 355-360 (1994).
24. T. P. Bleck: Convulsive disorders: the use of anticonvulsant drugs. Clin. Neuropharmacol. 13, 198-209 (1990).
25. C. J. van Boxtel, A. Rane, R. D. Brown, and J. T. Wilson: The formation of carbamazepine epoxide by rat liver microsomes: an investigation of the biphasic kinetic profile. Life Sci. 29, 2575-2584 (1981).
26. B. M. Kerr, K. E. Thummel, C. J. Wurden, S. M. Klein, D. L. Kroetz, F. J. Gonzalez, and R. H. Levy: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol 47, 1969-1979 (1994).
27. M. Pirmohamed, N. R. Kitteringham, A. M. Breckenridge, and B. K. Park: The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem. Pharmacol. 44, 2307-2314 (1992).
28. J. M. Hansen, K. Siersboek-Nielsen, and L. Skovsted: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmacol. Ther. 12, 539-543 (1971).
29. J. R. Y. Ross and L. Beeley: Interaction between carbamazepine and warfarin. Br. Med. J. 280, 1415-1416 (1980).
30. K. R. Rosenberry, C. J. Defusco, H. C. Mansmann, and S. J. McGeady: Reduced theophylline half-life induced by carbamazepine therapy. J. Pediatr. 102, 472-474 (1983).
31. A. A. Lai, R. H. Levy, and R. E. Cutler: Time-course of interaction between carbamazepine and clonazepam in normal man. Clin. Pharmacol. Ther. 24, 316-323 (1978).
32. P. J. Neuvonen, O. Penttila, R. Lehtovaara, and K. Aho: Effect of anti-epileptic drugs on the elimination of various tetracycline derivatives. Eur. J. Clin. Pharmacol. 9, 147-154 (1975).
33. M. Jerling, L. Linstrom, U. Bondesson, and L. Bertilsson: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therap. Drug Monit. 16, 368-374 (1994).
34. S. K. Panesar, J. M. Orr, K. Farrell, R. W. Burton, K. Kassahun, and F. S. Abbott: The effect of carbamazepine on valproic acid disposition in adult volunteers. Br. J. Clin. Pharmacol. 27, 323-328 (1989).
35. T. A. Bowdle, R. H. Levy, and R. E. Cutler: Effects of carbamazepine on valproic acid kinetics in normal subjects. Clin. Pharmacol. Ther. 26, 629-634 (1979).
36. A. B. M. Farghali-Hassan, L. Bossi, S. Garattini, M. Gerna, R. Gomeni, and P. L. Morselli: Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. Arch. Int. Pharmacodyn. Therap. 230, 125-139 (1976).
37. J. Wagner and K. Schmid: Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine. Xenobiotica 17, 951-956 (1987).
38. L. Regnaud, G. Sirois, and S. Chakrabarti: Effect of four-day treatment with carbamazepine at different dose levels on microsomal enzyme induction, drug metabolism and drug toxicity. Pharmacol. Toxicol. 62, 3-6 (1988).
39. R. Jung, P. Bentley, and F. Oesch: Influence of carbamazepine 10,11-oxide on drug metabolizing enzymes. Biochem. Pharmacol. 29, 1109-1112 (1980).
40. L. Cook, M. N. Nagi, J. Piscatelli, T. Joseph, M. R. Prasad, D. Ghesquier and D. L. Cinti: Hepatic subcellular distribution of short-chain β-ketoacyl coenzyme A reductase and trans-2-enoyl coenzyme A hydratase: 25- to 50-fold stimulation of microsomal activities by the peroxisome proliferator, di-(2-ethylhexyl)phthalate. Arch. Biochem. Biophys. 245, 24-36 (1986).
41. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964).
42. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
43. M. D. Burke, S. Thompson, C. R. Elcombe, J. Halpert, T. Haaparanta, and R. T. Mayer: Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337-3345 (1985).
44. A. J. Sonderfan, M. P. Arlotto, D. R. Dutton, S. K. McMillen, and A. Parkinson: Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255, 27-41 (1987).
45. S. Bandiera and C. Dworschak: Effects of testosterone and estrogen on hepatic levels of cytochromes P450 2C7 and P450 2C11 in the rat. Arch. Biochem. Biophys. 296, 286-295 (1992).
46. U. K. Laemmli: Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227, 680-685 (1970).
47. H. Towbin, T. Staehelin, and J. Gordon: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76, 4350-4354 (1979).
48. A. A. Elyas, N. Ratnaraj, V. D. Goldberg, and P. T. Lascelles: Routine monitoring of carbamazepine and carbamazepine-10,11-epoxide in plasma by high-performance liquid chromatography using 10-methoxy-carbamazepine as internal standard. J. Chromatogr. 231, 93-101 (1982).
49. A. Kumps, J. Genin-Ramakers, and Y. Mardens: Simultaneous determination of anticonvulsant drugs and metabolites in plasma by high-performance liquid chromatography. J. Chromatogr. 342, 469-471 (1985).
50. D. E. Ryan and W. Levin: Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 45, 153-239, (1990).
51. M. P. Arlotto, J. M. Trant, and R. W. Estabrook: Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicators of P450 identity and function. In "Methods in Enzymology" (M. R. Waterman and E. F. Johnson, ed.), vol. 206, pp. 454-462. Academic Press, San Diego, 1991.
52. P. L. Morselli, M. Gerna, and S. Garattini: Carbamazepine plasma and tissue levels in the rat. Biochem. Pharmacol. 20, 2043-2047 (1971).
53. T. Kamataki, K. Maeda, M. Shimada, and R. Kato: Effects of phenobarbital, 3-methylcholanthrene and polychlorinated biphenyls on sex-specific forms of cytochrome P-450 in liver microsomes of rats. J. Biochem. 99, 841-845 (1986).
54. H. M. Yeowell, D. J. Waxman, A. Wadhera, and J. A. Goldstein: Suppression of the constitutive, male-specific rat hepatic cytochrome P-450 2c and its mRNA by 3,4,5,3́,4́,5́-hexachlorobiphenyl and 3-methylcholanthrene. Mol. Pharmacol. 32, 340-347 (1987).
55. D. J. Waxman and L. Azaroff: Phenobarbital induction of cytochrome P-450 gene expresssion. Biochem. J. 281, 577-592 (1992).
56. P. E. Thomas, L. M. Reik, D. E. Ryan, and W. Levin: Regulation of three forms of cytochrome P-450 and epoxide hydrolase in rat liver microsomes. Effects of age, sex, and induction. J. Biol. Chem. 256, 1044-1052 (1981).
57. N. M. Wilson, M. Christou, and C. R. Jefcoate: Differential expression and function of three closely related phenobarbital-inducible cytochrome P-450 isozymes in untreated rat liver. Arch. Biochem. Biophys. 256, 407-420 (1987).
58. K. O. Cooper, L. M. Reik, Z. Jayyosi, S. Bandiera, M. Kelley, D. E. Ryan, R. Daniel, S. A. McCluskey, W. Levin, and P. E. Thomas: Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch. Biochem. Biophys. 301, 345-354 (1993).